Irazú Oncology is a Baltimore-based biotech company developing cancer immunotherapies using a proprietary Outer Membrane Vesicle (OMV) platform licensed from the University of Maryland. OMVs are naturally derived nanoparticles that deliver tumor-specific antigens to the immune system without requiring adjuvants, generating potent immune activation and durable anti-tumor memory.

The lead candidate, IRZ-03, represents the next frontier in cancer treatment through its dual-targeting approach: attacking cancer cells via MUC1 and CEA antigens while modulating the immunosuppressive tumor microenvironment through IDO/TDO pathway inhibition. Following positive FDA Pre-IND feedback in 2025, Irazú is advancing toward IND submission.

Advantages of The OMV platform: off-the-shelf availability, cost-effective manufacturing, no cold-chain requirements, and multi-epitope targeting. This positions Irazú to deliver accessible, scalable immunotherapies for underserved patient populations worldwide.